サードスペース内での使い捨て内視鏡プラットフォーム
サードスペース内視鏡処置における使い捨て内視鏡プラットフォームの有効性、実現可能性、安全性を実証するパイロット前向き試験
This is a prospective, single-arm unblinded study performed at a single tertiary center in the United States. All subjects will receive standard medical care and no experimental interventions are going to be performed. The procedures will be performed by Dr. Mohamed Othman, Dr. Salmaan Jawaid, Dr. Tara Keihanian, and Dr. Fares Ayoub. All patients undergoing third space endoscopic procedures including e-POEM and g-POEM, meeting study inclusion criteria will be screened by study coordinators for preliminary eligibility and those who meet the inclusion criteria will be approached individually for further discussion about the study and obtaining informed consent.
The goal of this prospective, pilot trial is to demonstrate the efficacy, feasibility, safety, and clinical outcomes of third space endoscopic procedures completed using a disposable endoscope platform.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Over the past decade, therapeutic endoscopy has rapidly progressed giving rise to the fields of third space endoscopy and endoscopic surgery. In the foregut, esophageal per-oral endoscopic myotomy (e-POEM) has become the standard approach for achalasia with level I data supporting its use1. For gastroparesis, randomized clinical trial data 2 now supports gastric POEM (g-POEM) use for refractory cases with promising results particularly in diabetic and post-surgical patients.
Despite the remarkable advances in endoscopic therapy, there has been comparably slower progress in innovation for endoscopic platforms. In fact, current endoscope design is not significantly different from the earliest endoscopes where tip deflection is primarily controlled by rotating dials on the shaft of the endoscope and insufflation and suction are controlled by manual pressure-controlled buttons. Original fiberoptic gastroscopes were designed to facilitate diagnostic use, where the endoscopist manipulates tip-deflection dials using both hands while viewing the intestinal mucosa through a viewer, with an assistant moving the shaft of the endoscope. This same design was then adapted for colonoscopy, and later for duodenoscopy and endoscopic ultrasound. Despite significant progress in image quality, the endoscope remains a heavy device, requiring significant dexterity and musculoskeletal fitness on behalf of the endoscopist to perform endoscopy ergonomically without risking muscle injury. In addition, endoscopes require several supportive devices to function, including a separate water pump, video processor, computer screen and if needed an electrosurgical generator, making the portability of traditional endoscopic platforms quite limited.
More recently, rising concerns about infectious complications from reusable endoscopes have led to the development of several single-use endoscope platforms. A novel disposable endoscope (AMBU single-use disposable gastroscope; AMBU USA, Columbia, Md, USA) was recently approved by the U.S. Food & Drug Administration (FDA) in 2022 for use in humans. This endoscopic platform is designed for single use and comes with several advantages compared to traditional reusable endoscopes. The platform is significantly lighter, with a weight of 650 grams compared to a traditional reusable upper endoscope which weighs approximately 3900 grams. Additionally, the single use platform has a wider depth of field and significantly smaller video processor and built in portable screen. These advantages have led our group to use the endoscope for therapeutic foregut procedures including e-POEM and g-POEM with positive results. The investigators at Baylor College of Medicine most recently published a proof-of-concept experience 3 in using the disposable gastroscope for a case of e-POEM, where the significantly lighter weight of the endoscope allowed easier maneuverability and subjectively lower musculoskeletal strain for the performing endoscopist, with no negative effects on image quality or technical aspects of the procedure.
Before wider adoption, these perceived benefits need to be demonstrated in a larger, prospective trial confirming non-inferiority to historical data from reusable platforms and safety.
研究の種類
研究の種類
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
All patients 18 years or older, not pregnant (if a woman), consenting to the study, and presents for an Esophageal POEM, or Gastric POEM will be invited to participate on this study.
説明
Inclusion Criteria:
- Patient is ≥ 18 years old.
- Patients can provide informed consent.
- Patient is referred for third space endoscopic procedure including e-POEM, g-POEM.
Exclusion Criteria:
- Patient is < 18 years old.
- Patient refused and/or unable to provide consent.
- Patient is a pregnant woman.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Technical Success
時間枠:Day 1 (procedure day)
|
Defined as the ability to perform entire myotomy (procedure) with the disposable endoscope. |
Day 1 (procedure day)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total Procedure Time
時間枠:During Procedure
|
Total recorded time to perform procedure using disposable endoscope |
During Procedure
|
|
Intraprocedural adverse events
時間枠:During Procedure
|
Adverse events emerging during procedure |
During Procedure
|
|
Satisfactory scores on Endoscopist satisfaction
時間枠:Immediately following completion of the procedure
|
Satisfactory survey: with endoscope maneuverability (1-5 Likert scale; 1 being "strongly disagree" to 5 being "strongly agree"), with endoscope functionality [insufflation, suction, accessory passage] (1-5 Likert scale), with endoscope image quality (1-5 Likert scale; 1 being "strongly disagree" to 5 being "strongly agree"). |
Immediately following completion of the procedure
|
|
Scores on musculoskeletal strain survey
時間枠:Immediately following completion of the procedure
|
Musculoskeletal Strain survey: Focused on Overall strain, wrist strain, shoulders strain, and neck strain |
Immediately following completion of the procedure
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Mohamed Othman, MD、Baylor College of Medicine
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- H-55176
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
There are no plans to share IPD to other researchers.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。